Fundraising Fox

Resolution Therapeutics

1 known investors

resolution-tx.com ↗

Resolution Therapeutics develops Regenerative Macrophage Therapy, a cell therapy for patients with end-stage liver disease intended to help damaged livers recover and slow disease progression. Its EMERALD early-stage clinical trial is running in the UK and Spain.

BiotechHealthtech

Investors · 1

SynconaLondon

In the news

Resolution Therapeutics - BIO Investment & Growth Summit 2026bigs.bio.org · Mar 2026Resolution Therapeutics Secures $65 Million in Funding to Revolutionize Inflammatory Organ Disease Treatment with Macrophage Cell Therapy | Signalbasetrysignalbase.com · Oct 2024Syncona ploughs £63.5m into Resolution Therapeutics - QuotedDataquoteddata.com · Oct 2024Resolution Therapeutics raises $85 million to advance its macrophage therapylabiotech.eu · Oct 2024Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment - Resolution Therapeuticsresolution-tx.com · Oct 2024News - Resolution Therapeuticsresolution-tx.com · Mar 2021

Frequently asked questions

What does Resolution Therapeutics do?
Resolution Therapeutics develops Regenerative Macrophage Therapy, a cell therapy for patients with end-stage liver disease intended to help damaged livers recover and slow disease progression. Its EMERALD early-stage clinical trial is running in the UK and Spain.
Who are Resolution Therapeutics's investors?
Resolution Therapeutics's investors include Syncona.